 This study found that rheumatoid arthritis, I, patients have higher levels of soluble interleukin, one receptor antagonist, Illinois, one RA, and its M-I-N-A expression compared to control subjects, and that the Illinois I-N-V-N-T-R polymorphism is associated with I risk and regulation of Illinois, one RA expression. Additionally, high expression of Illinois, one RA was detected in I patients under treatment or not with anti-romatic drugs, and carriers of Illinois I-R-N-2 genotype had higher Illinois, one RA expression than carriers of other genotypes. This article was authored by S. Ramirez Perez, Eudela Cruz-Mosso, J. Hernandez-Bello, and others.